Das Zentrum
Multiple Sklerose Zentrum Dresden
Patienteninformation
Kontaktinformation
Behandlungsteam
Studienteam
Neuropsychologie
Mobilitätszentrum
Das Mobilitätszentrum
Ganganalyse
Sprunganalyse
DIERS
EMIQ
Forschungsprojekte
Neuroimmunologisches Labor
Das NIL
Neurofilament-Leichtketten Analyse
Autonomes & Neuroendokrinologisches Funktionslabor
Das ANF
Untersuchungsmethoden
MS Living Lab
Management & Science
Team Management & Science
Projekte
eHealth & Analytics
MSDS 3D
MSDS Klinik & Praxis
MS-HRS
MTRS
MS Management
Aktuelles
Neuigkeiten
Publikationen
Veranstaltungen
Adventssymposium
Multiple Sklerose 360°
Welt-MS-Tag 2021
Doktorarbeiten
Jobs
Kontakt
Podcasts & Newsletter
Newsletter
Patienten-Podcast
Ärzte-Podcast
Neurovision
Immunzellkalender 2025
Sherlock-MS-Blog
Studien
Interventionelle Studien
B-SHUTTLE
Nicht-interventionelle Studien
MS PATHS
Konectom
Sprachanalyse
Deutsch
Deutsch
English
Letter to the editor regarding “Therapeutic drug monitoring of natalizumab”
MS Treatments
Jahr
Publikationsjahr
2020
Autoren
Autorenliste der Publikation
Proschmann U, Sehr T, Akgün K, Ziemssen T.
Verlag
Publisher-Information
Mult Scler J 2020;26(6):741-742.
Link
Zur Publikation (externer Server)
https://doi.org/10.1177/1352458519837702
Tags
Forschungsthemen
Multiple Sklerose
MS Behandlung
Treatments
2020
CONFIDENCE treatment success: long-term real-world effectiveness and safety of ocrelizumab in Germany
MS Treatments
Jahr
2025
RECLAIM—A retrospective, multicenter observational study aimed at enabling the development of artificial intelligence-driven prognostic models for disease progression in multiple sclerosis
MASC
Jahr
2025
Tolebrutinib in Nonrelapsing Secondary Progressive Multiple Sclerosis
MASC
Jahr
2025
Extensive T-Cell Profiling Following SARS-CoV-2 mRNA Vaccination in Multiple Sclerosis Patients Treated with DMTs
NIL
Jahr
2025
Long-term efficacy and safety of alemtuzumab in participants with highly active MS: TOPAZ clinical trial and interim analysis of TREAT-MS real-world study
MS Treatments
Jahr
2025
